82 results about "Orciprenaline" patented technology

The invention provides a preparation method of a mineralized collagen scaffold material with a bionic structure, and belongs to the field of biomedical engineering.The preparation method comprises the steps that an amorphous calcium phosphate solution stabilized by polyacrylic acid is prepared, and the molar ratio of Ca to P in the amorphous calcium phosphate solution is 1.67: 1; preparing a collagen solution containing noradrenaline; carrying out isoelectric focusing treatment on the collagen solution under a constant voltage to form a dense membrane, and stretching the dense membrane to generate 120-200% deformation, so as to obtain a collagen membrane with a bionic structure; and soaking the collagen membrane in the amorphous calcium phosphate solution, and then performing freeze drying to obtain the noradrenaline-mineralized collagen scaffold material. The mineralized collagen scaffold material prepared by the method has excellent biocompatibility, osteogenesis inductivity and sufficient mechanical strength, can effectively promote bone tissue defect repair, and has a good application prospect in the field of bone tissue engineering. The invention further provides the mineralized collagen scaffold material with the bionic structure and application of the mineralized collagen scaffold material.

The invention discloses a detection method of catecholamine substances and metabolites thereof, freeze-dried powder and application of the freeze-dried powder. The detection method of catecholamine and metabolites thereof comprises the following step: detecting a sample to be detected by adopting a liquid chromatography-tandem mass spectrometry method. According to the present invention, the sample pretreatment and the detection condition optimization are performed so as to achieve the efficient and accurate detection of noradrenaline, epinephrine, variepinephrine, noradrenaline, dopamine and 3-methoxytyramine, the sensitivity is high, the specificity is good, and the new reliable detection method is provided for the detection of catecholamine and metabolites thereof in the blood sample.

The invention discloses a preparation method and application of a mesenchymal stem cell exosome-loaded absorbable suture line, noradrenaline is utilized to activate the surface of a collagen suture line, then human umbilical cord mesenchymal stem cell exosomes are assembled to the surface of the activated suture line through a soaking method, and the absorbable suture line with the surface functionalization is constructed. After the suture line is used, the wound healing effect is good, the blood vessel and cell recovery degree is good, proliferation and migration of fibroblasts can be remarkably promoted, proliferation of T lymphocytes and Th1 cells is effectively inhibited, and a powerful guarantee is provided for tissue repair.

The invention provides a method for synchronously detecting eight catecholamines and metabolites thereof based on liquid chromatography-tandem mass spectrometry and application of the method. The detection method comprises the following steps: mixing a plasma or urine sample to be detected with an internal standard and acetonitrile; centrifuging, taking supernate, blowing liquid with nitrogen, and adjusting the pH value; mixing the supernate with a propionic anhydride solution, and carrying out derivatization reaction to obtain a test solution; performing liquid chromatography-tandem mass spectrometry detection on the test solution and the standard solution, separating dopamine, epinephrine, noradrenaline, epinephrine, noradrenaline, 3-methoxytyramine, homovanillic acid and vanillic mandelic acid by liquid chromatography, and determining the concentration of the standard substance as an X axis by using a mass spectrometry isotope internal standard quantification method. The ratio of the peak area of the standard substance to the peak area of the internal standard substance is the Y axis, establishing a standard curve, and calculating the concentrations of catecholamine and the metabolites thereof in the test solution. The method is high in detection efficiency, high in sensitivity and good in equipment compatibility, the detection time is shortened, and the cost can also be saved.

The invention relates to a construction method and application of a loneliness mouse model, and the method comprises the steps: placing an experimental mouse in an isolation region in a transparent acrylic isolation cover through an environment in which physical isolation and social deprivation stimulation coexist, forming a visually accessible but physically isolated social environment with five normal living mice, and continuously inducing chronic loneliness for 4 weeks. The effectiveness of the model is verified through a multi-dimensional evaluation system, including behavioristics (open field, elevated maze and three-box experiment), neuroendocrine (serum noradrenaline and angiotensin II), immune inflammatory factors (IL-1beta, IL-6, TNF-alpha and CCL5) and nerve activation (blue spot, almond nucleus, lateral nucleus septum, medial prefrontal cortex and center joint dorsal nucleus C-Fos staining) indexes. According to the intervention method, dynamic environment abundance and social stimulation are adopted, running wheels are arranged, a modular abundance device is arranged, and a social environment of new mice is introduced, so that pathological phenotypes caused by loneliness are reversed. And a systematic experiment tool is provided for exploring association of aloneness and diseases.

Methods for treating a subject with multiple system atrophy (MSA) using ampleloxetine or a pharma- ceutically acceptable salt thereof are disclosed. The disclosed methods include using ampleloxetine or a pharma- ceutically acceptable salt thereof to (i) treat symptoms of neurogenic orthostatic hypotension in a subject with MSA, (ii) reduce the magnitude of the decline in quality of life in a subject with MSA, and / or (iii) increase the level of norepinephrine in a subject with MSA.

The application discloses a preparation method and application of a conjugate targeting pelvic autonomic nerves, wherein the conjugate is NE-RH formed by coupling of rhein and norepinephrine, the conjugate can realize precise targeting of norepinephrine neurons, improve the accumulation effect of RH in the norepinephrine neurons, and further enhance the nerve protection effect of RH. The conjugate has a molecular weight of less than 1000 Da, can help to penetrate the blood-brain barrier, and can avoid the defects of being easily removed by a mononuclear phagocyte system and having a short half-life. The production process of the conjugate is simple, the chemical coupling reaction is clear, the yield can reach 38%, and the purity of the product is greater than 99%, so that the conjugate is convenient to popularize and use. The conjugate and the preparation method have important significance for the damage repair of pelvic autonomic nerves.

The present invention relates to a novel Noradrenergic and Specific Serotonergic Anxiolytic and Antidepressant (NaSSA) and a method for the production and use thereof for treating mental disorders.The subject of this invention is a novel noradrenergic and specific serotonergic drug for the treatment of mental disorders in humans, which is 2,8-dimethyl-5-(2-phenylethyl)-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole hydrochloride (A·HCl), a polymorphous modification thereof, and methods for the production and use thereof.

The present invention provides a bioluminescence probe for detecting norepinephrine, its preparation method and use, belonging to the field of biological detection. The bioluminescence probe of the present invention has high selectivity and high responsiveness to norepinephrine, can specifically recognize norepinephrine, has high sensitivity and low detection limit, and can be used for the precise detection of norepinephrine. In the range of pH 1.0 to 7.4, the bioluminescence probe of the present invention has excellent stability and can meet the application requirements under different physiological environments in vivo. At the same time, the norepinephrine bioluminescence probe of the present invention can also visually track exogenous norepinephrine at the in vivo level, and perform dynamic visual analysis on patients with diseases related to abnormal expression of norepinephrine involving nerves, tumors, blood pressure and heart diseases, which is beneficial to the clinical detection of norepinephrine and has broad application prospects.

The present disclosure relates to a pharmaceutical composition comprising a therapeutically effective amount of latrepirdine or a pharmaceutically acceptable salt thereof and an effective amount of a PK stabilizer. The PK stabilizer may be selected from the group consisting of paroxetine, fluoxetine, and quinidine or a pharmaceutically acceptable salt thereof. The PK stabilizer in the composition results in improved pharmacokinetic profile and enhanced therapeutic effect of latrepirdine. The disclosure further relates to treatment of disorders associated with noradrenergic hyperarousal using the pharmaceutical composition.

The invention belongs to the technical field of human body electroencephalogram signal processing and brain regulation and control, and provides a noradrenaline oscillation time-frequency-phase three-dimensional coupling sleep coordinated regulation and control device which comprises the following steps: calculating a three-dimensional coupling coefficient by combining a time domain correlation coefficient, a frequency domain correlation coefficient and an instantaneous phase difference between multi-modal physiological signals; determining the coupling state of the signal based on the three-dimensional coupling coefficient and a preset threshold value; predicting to obtain an optimal regulation factor and a modal weight based on a coupling coefficient matrix constructed based on a time domain correlation coefficient and a frequency domain correlation coefficient and a constructed three-dimensional coupling double-layer optimization architecture in combination with the multi-modal physiological signal; calculating the optimized stimulation intensity in combination with the modal weight, the optimal regulation factor and the multi-modal signal characteristic parameters; and adaptively selecting a stimulation mode and outputting a stimulation signal according to the coupling state of the current multi-mode signal and the optimized stimulation intensity. Accurate matching of stimulation parameters and nerve-blood vessel-cerebrospinal fluid system collaborative rhythm is realized.

The present disclosure relates to a method of treatment or prophylaxis of a preterm infant by administering intravenously a therapeutic amount of a composition comprising IGF-1 and IBGBP-3 in combination with a therapy selected from the group comprising: caffeine, fentanyl, fluconazole, gentamicin, insulin, midazolam, morphine, low dose norepinephrine, vancomycin concentrations of 5 mg / ml or less, parenteral nutrition (or a composition for the same use) and combinations thereof.

The application relates to a reagent combination for detecting depression, a manufacturing method, a detection system and application thereof, and belongs to the technical field of instrument detection. The reagent combination for detecting depression comprises a calibrator, a quality control sample and an extraction solution of a to-be-detected compound serving as a biomarker; wherein the to-be-detected compound is at least three kinds selected from 5-hydroxyanthranilic acid, methionine, gamma-aminobutyric acid, 3,4-dihydroxyphenylacetic acid, 2-picolinic acid, quinolinic acid, kynurenine, 5-hydroxytryptamine, 3-hydroxykynurenine, 3-hydroxyanthranilic acid, dopamine and norepinephrine. The reagent combination for detecting depression and the detection system can significantly improve the accuracy of diagnosis, are convenient to detect, have good repeatability of detection data, are high in specificity, and are accurate in clinical diagnosis results.

The invention provides a method for efficiently preparing chiral alpha-nitroalcohol, and relates to the technical field of chemical synthesis. The invention provides a method for converting nitroketone into nitroalcohol, and the obtained alpha-nitroalcohol compound can be used as an intermediate for synthesizing a plurality of important drugs (such as noradrenaline) and has very high economic value. The asymmetric catalytic hydrogenation method provided by the invention is high in efficiency, quantitative in yield and excellent in enantioselectivity, and greatly reduces the difficulty and cost of synthesis of various drugs. # imgabs0 #

The present disclosure relates to the treatment of agitation caused by noradrenergic hyperarousal in an agitated subject. The present disclosure provides oromucosal dosage forms comprising effective amounts of latrepirdine either alone or in combination with dexmedetomidine or pharmaceutically acceptable salts thereof and one or more pharmaceutically acceptable carriers and / excipients. Methods of their use are also provided. The present disclosure also provides a method of treating depression by administering oromucosally a therapeutically effective amount of dexmedetomidine alone or in combination with latrepirdine.

The invention belongs to the technical field of human body electroencephalogram signal processing and brain regulation and control. The invention provides an ultrasonic-electrical stimulation collaborative lymphatic system enhanced closed-loop regulation and control system, which integrates noradrenaline oscillation core driving signals to realize sleep staging and conversion detection, decides an ultrasonic-electrical stimulation collaborative mode based on a staging coupling index, completes parameter linear transition in a conversion period, and improves sleep quality. Stimulation parameters are dynamically optimized in combination with reinforcement learning and a PID fusion algorithm. According to the device, the defects of core signal deficiency, inaccurate stimulation coordination, one-sided coupling analysis and poor safety adaptability of an existing device are overcome, the lymphatic system metabolic waste removal efficiency is remarkably improved, the sleep interruption risk is reduced, regulation and control are accurate, safety and noninvasive are achieved, the device is suitable for prevention and adjuvant therapy of neurodegenerative diseases such as Alzheimer's disease, and the device has a wide application prospect. And the method can also be expanded to be used for lymphatic-like function mechanism research and early disease screening.

The invention relates to a method for the synthesis of (1R)-2-(dibenzylamino)-1-(3,4- dibenzyloxyphenyl)ethanol of formula (I): (I), to said compound of formula (I), and to the use thereof as an intermediate in the synthesis of noradrenaline.

The invention discloses a sleep deprivation marker identification method based on WGCNA and machine learning, and relates to the technical field of sleep deprivation markers. The method specifically comprises the following steps: S1, data acquisition and test design; s2, differential gene identification; s3, function enrichment; s4, WGCNA analysis is carried out; s5, LASSO calculation is carried out; s6, performing a sleep deprivation mouse model experiment; s7, determining noradrenaline by using an enzyme-linked immunosorbent assay method; s8, a Western blot western blot test is carried out; s9, analyzing immune characteristics; and S10, statistical analysis. According to the invention, two hub genes KLRD1 and SPON2 related to sleep deprivation are screened through bioinformatics and machine learning methods, the important role of KLRD1 in SD is confirmed, a new SD biomarker SPON2 is identified, and the immune spectrum in the SD state is comprehensively analyzed for the first time on the genetic level.

The application discloses application of a norepinephrine inhibitor in preparation of a medicine for treating or relieving corneal limbal stem cell deficiency, and belongs to the technical field of medicines.The experiment proves that sympathetic nerves are excessively activated in a mouse model of corneal limbal stem cell deficiency, and the release of norepinephrine is increased, and the experiment proves that 6-hydroxydopamine hydrochloride can destroy sympathetic nerves to inhibit the release of norepinephrine, and a tyrosine hydroxylase inhibitor can inhibit the synthesis of norepinephrine, and both can further relieve the symptoms of corneal limbal stem cell deficiency.The norepinephrine inhibitor can improve the corneal limbal microenvironment, reduce corneal neovascularization, reduce corneal epithelialization, enhance corneal transparency and relieve corneal edema, and provides a new direction and a new way for the pathogenic mechanism and intervention target of corneal limbal stem cell deficiency, and has a wide application prospect.

The invention relates to the technical field of analysis and detection, in particular to a kit and a method for extracting catecholamine and metabolites thereof based on a paramagnetic particle method and a method for detecting catecholamine and metabolites thereof by LC-MS / MS (liquid chromatography-mass spectrometry / mass spectrometry). The kit comprises magnetic beads, an activating solution, an eluent, a washing solution, a leacheate I, a leacheate II and a derivatization reagent, the catecholamine and the metabolite thereof comprise one or more of dopamine hydrochloride, epinephrine, noradrenaline hydrochloride, methoxynoradrenaline hydrochloride, methoxyepinephrine hydrochloride and 3-methoxytyramine hydrochloride. The in-vivo concentration of catecholamine and metabolites thereof in human plasma and urine is detected in a high-flux manner by adopting a magnetic bead and derivation method, and the kit has the characteristics of high sensitivity, good repeatability, high accuracy, good specificity and the like.

The disclosure provides methods for treating major depressive disorder in a human patient having moderate or severe anhedonia. The methods comprise administering to the patient in need thereof an effective amount of aticaprant, or a pharmaceutically acceptable salt thereof. In some embodiments, the patient had an inadequate response to other antidepressant therapy prior to treatment with aticaprant. In other embodiments, the other antidepressant therapy comprised a selective serotonin reuptake inhibitor (SSRI), serotonin-norepinephrine reuptake inhibitor (SNRI), or a combination thereof.

The present invention provides a monoamine transmitter reuptake inhibitor and a preparation method therefor and a pharmaceutical composition thereof, and further relates to a use of the compound or the pharmaceutical composition in preparation of a drug for preventing or treating dopamine (DA), norepinephrine (NE), 5-hydroxytryptamine (5-HT), and / or sigma-1 receptor-mediated related diseases.

The invention discloses a to-be-detected sample pretreatment method, a method for simultaneously detecting multiple neurotransmitters and a kit, and the to-be-detected sample pretreatment method comprises the following steps: carrying out pretreatment on a to-be-detected sample by adopting WCX solid-phase extraction magnetic beads; the to-be-detected sample is treated and then is used for detection by adopting an isotope internal standard method and a liquid chromatography-tandem mass spectrometry method at the same time. According to the technical scheme, multiple neurotransmitters, especially one or more of dopamine, noradrenaline, 5-hydroxytryptamine, gamma-aminobutyric acid and melatonin can be accurately detected at the same time, the method has very high sensitivity, the to-be-detected substance in the sample is enriched while automatic sample treatment is achieved, the detection sensitivity is high, and the detection accuracy is high. Complex operation is not needed, the pretreatment time is greatly shortened, combined detection of metabolites of different concentration levels is achieved, interference of complex matrixes on target detection is eliminated, the method is rapid and stable, and the kit can be stable for 2 years at the temperature of 2-8 DEG C.

The invention relates to the field of biological medicine, in particular to application of a quinic acid derivative. The quinic acid derivative comprises one or two of 3-O-p-coumaroyl quinic acid and 4-O-p-coumaroyl quinic acid, and the quinic acid derivative comprises one or two of 3-O-p-coumaroyl quinic acid and 4-O- The applications include treatment and / or prevention of depression. The quinic acid derivatives 3-O-p-coumaroyl quinic acid and 4-O-p-coumaroyl quinic acid can be used for improving the behavioristics of depressive mice; the compound can significantly increase dopamine and noradrenaline in the brain of a depressive mouse, reduce the levels of inflammatory factors IL-6 and TNF-alpha in the brain of the depressive mouse, increase the intestinal microbial diversity of the depressive mouse and significantly increase the BDNF level in the brain of the depressive mouse, and can be used as a drug for treating and / or preventing depression.

The invention discloses a method for rapidly and simultaneously detecting catecholamine substances and creatinine in urine, relates to the technical field of clinical content and concentration analysis and detection of nerve substances, and adopts LC-MS / MS (liquid chromatography-mass spectrometry / mass spectrometry) to perform system integration development of multiple indexes. Seven items, including dopamine, epinephrine, noradrenaline, alphinephrine, noradrenaline, homovanillic acid and vanillic mandelic acid, of urine catecholamine and metabolites are developed and used for detecting pheochromocytoma and paraganglioma; the seven items include the dopamine, the epinephrine, the noradrenaline, the alphinephrine, the homovanillic acid and the vanillic mandelic acid; seven indexes can be detected at a time, the kit can be used for detecting random urine, great convenience is brought to patients, meanwhile, the seven indexes are analyzed together, and specificity and sensitivity of PPGL detection are improved; random urine detection needs the ratio of seven indexes to creatinine, creatinine in urine is often used as an internal reference and is used for concentration correction when substances in urine are excreted, the concentration of catecholamine and catecholamine metabolites in urine is corrected according to the content of creatinine in urine, and the influence of renal functions and drinking water factors on results is reduced.

The invention provides carbon-14-labeled epinephrine and a preparation method thereof, carbon-14-labeled noradrenaline and a preparation method thereof, and belongs to the field of radioactive chemistry. The invention provides a carbon-14 labeled epinephrine or a carbon-14 labeled noradrenaline, wherein the carbon-14 label is located at the a position of the benzene ring of the epinephrine or the noradrenaline. According to the present invention, the epinephrine and the noradrenaline are subjected to carbon-14 labeling, such that the metabolite ratio can be quantitatively analyzed, the dynamic conversion rule of the metabolite in the human body can be revealed, the drug administration scheme can be easily optimized, the toxicological mechanism can be easily clarified, the theoretical basis can be provided for the clinical safety application, and the scientific development of the first-aid drug can be promoted.

The invention discloses application of a ganoderma lucidum extract in preparation of a product for improving skin problems, bidirectional regulation of skin homeostasis is realized through a dual-action mechanism, on one hand, conversion of corticosterone to cortisol is inhibited, and on the other hand, the skin homeostasis is inhibited; the problems of skin barrier injury, skin basement membrane injury, excessive sebum secretion, accelerated aging and the like caused by excessive cortisol are relieved; on the other hand, by inhibiting differentiation of macrophages induced by noradrenaline to inflammation phenotypes, the cortisol level is reduced, meanwhile, the skin inflammation response excited by early pressure is effectively controlled, and bidirectional regulation of skin homeostasis is achieved.

The invention belongs to the technical field of monoamine neurotransmitter detection, and particularly relates to a method and kit for extracting and detecting the concentration of monoamine neurotransmitters in saliva based on a magnetic solid-phase extraction method, and the method comprises the following steps: taking a saliva sample, and adding magnetic solid-phase extraction magnetic beads with a weak cation exchange function and a methanol-containing aqueous solution as internal standards; the steps of activation, balancing, sample loading, leaching and elution are sequentially carried out, and the composition of an eluent is compatible with that of a high performance liquid chromatography mobile phase; carrying out separation and detection by adopting a liquid chromatography-electrochemical detector; and calculating the content of the monoamine neurotransmitter in the saliva sample according to a standard curve established by the internal standard. According to the invention, the extraction of epinephrine, noradrenaline, dopamine and serotonin can be automatically and quickly realized. A saliva sample is not filtered, and the phenomenon that the sample cannot flow out due to large particulate matter blocking the sieve plate is avoided. The operation difficulty is reduced, the eluent does not need to be subjected to nitrogen blowing treatment again, and the loss of a target object and the fluctuation of the recovery rate are avoided.

The invention belongs to the technical field of bioelectronic medicine, and provides a sleep regulation and control system and method based on neurotransmitter and vascular power bidirectional coupling, and the system comprises a neurotransmitter detection module which is configured to correct a detection voltage according to the change of the local temperature of a detection part, the concentration of noradrenaline is obtained in real time by combining feedback regulation of a detection voltage correction value; the blood vessel phase calculation module is configured to calculate the phase difference fed back by the blood vessel pulsation in combination with the blood vessel diameter change rate and the noradrenaline concentration; the stimulation signal generation module is configured to consider the obtained detection voltage correction value and the phase difference to construct a multi-mode stimulation signal generation equation; and the regulation and control module is configured to dynamically adjust parameters of the constructed multi-mode stimulation signal generation equation in combination with the noradrenaline concentration and the blood vessel state, obtain and analyze an electrophysiological signal, track the physiological signal and complete effective sleep regulation and control based on neurotransmitter and blood vessel dynamic bidirectional coupling.

The invention discloses a fluorescent probe as shown in a formula I or II for detecting noradrenaline and epinephrine and application of the fluorescent probe in cell imaging and biosensing. The fluorescent probe for detecting noradrenaline can be specifically combined with noradrenaline, two-channel ratio-type fluorescence change is presented, a ratio-type signal has a self-calibration function, and higher accuracy is provided for quantitative analysis. The fluorescent probe for detecting the epinephrine can be specifically combined with the epinephrine and shows low-background opening type fluorescence change. The fluorescent probe has high sensitivity and selectivity, can realize quantitative detection of noradrenaline and epinephrine in serum and fluorescence imaging in cells, has the potential to be used as an effective tool for evaluating the sympathetic nerve activity degree in diseases such as hypertension, has a wide application prospect, and has a wide application prospect. And the detection means of catecholamine substances are enriched.